Clinical Trials Logo

Non-Small Cell Lung Cancer clinical trials

View clinical trials related to Non-Small Cell Lung Cancer.

Filter by:

NCT ID: NCT05380024 Recruiting - Clinical trials for Non Small Cell Lung Cancer

A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

Start date: August 17, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase II, single-Arm, prospective study of neoadjuvant Ensartinib for the treatment of patients with ALK positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer

NCT ID: NCT05379803 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

EGFR mutated NSCLC patiens with CNS metastases have poor prognosis. High-dose furmonertinib (160mg/day) have produced high CNS PFS and ORR in second-line for EGFR T790M mutated NSCLC. Whether EGFR mutated NSCLC with CNS metastases can benefit from first-line treatment of high-dose furmonertinib has not been reported. This study aims to investigate the efficacy and safety of high dose furmonertinib in first-line treatment of EGFR mutated NSCLC patiens.

NCT ID: NCT05378334 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

This is a double-blind, randomized controlled study evaluating the efficacy and safety of HGXJT in combination with ICI-based standard treatment in lung cancer patients with bone metastases. Enrolled participates will randomly receive HGXJT or placebo during the first 4-6 cycles of ICI-based standard treatment.

NCT ID: NCT05377658 Recruiting - Clinical trials for Non-small Cell Lung Cancer

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Start date: July 26, 2022
Phase: Phase 2
Study type: Interventional

AK104, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of AK104 with chemotherapy as neoadjuvant and adjuvant therapy for patients with resectable stage II-IIIA NSCLC.

NCT ID: NCT05375994 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

RAMP204
Start date: August 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.

NCT ID: NCT05375084 Recruiting - Solid Tumor Clinical Trials

SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Start date: October 20, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study of BBP-398, a SHP2 inhibitor, in combination with nivolumab, a PD-1 antibody, in patients with NSCLC with a KRAS mutation. The study involves 2 parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion.

NCT ID: NCT05374538 Terminated - Clinical trials for Non-small Cell Lung Cancer

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

Start date: November 9, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1a/1b study of aurora kinase A inhibitor VIC-1911 administered as monotherapy and in combination with sotorasib for the treatment of locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer(NSCLC).

NCT ID: NCT05369312 Not yet recruiting - Colorectal Cancer Clinical Trials

Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients

Start date: June 2022
Phase: Phase 1
Study type: Interventional

A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.

NCT ID: NCT05366478 Recruiting - Melanoma Clinical Trials

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Start date: May 30, 2022
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.

NCT ID: NCT05363319 Recruiting - Clinical trials for Non-small Cell Lung Cancer

An Observational Study to Assess the Effectiveness and Safety of Cemiplimab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (CEMI-LUNG)

CEMI-LUNG
Start date: October 27, 2022
Phase:
Study type: Observational [Patient Registry]

Primary Objective: Describe the overall survival rate (OS) rate in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice. Secondary Objectives: - To describe the following in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice: - Objective response rate (ORR) - Time to response (TTR) - Time to progression - Time to first subsequent anti-NSCLC treatment (TTST) - Duration of response (DoR) - Progression-free Survival (PFS) - Incidence and severity of adverse events (AEs) in patients with advanced NSCLC treated with a cemiplimab-based regimen in routine clinical practice